為什麼腫瘤首次人體試驗在開始前就可能失敗
關於場地組合、方案假設、啟動延遲和隱藏執行風險的觀點。
洞察
早期腫瘤開發中，哪些訊號值得先看？
這裡整理公開研究、腫瘤會議訊號和我們對 FIH 執行風險的觀點。Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方來源會作為可篩選的資訊補充，所有卡片保留原始公開連結。
重點觀點
先看那些申辦方通常發現得太晚的問題。
這些固定主題讓洞察頁先有清楚判斷：外部公開來源能同步時作為補充，無法同步時頁面也不會變成空的資訊庫。
場地級啟動風險與傳統可行性評估
為什麼平均值和聲譽型專家選擇可能錯過真正重要的執行尾部風險。
中國創新藥如何進入全球開發語境
全球開發策略、區域選擇和試驗設計如何影響中國以外市場的可信度。
腫瘤場地選擇應如何按機制區分
ADC、雙抗、KRAS、CAR-T、放射性配體、DDR 資產和 TKI 不應使用同一套場地邏輯。
公開資訊庫
公開研究與腫瘤會議訊號
把 Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方公開來源放在同一個列表裡。可按來源、主題和關鍵詞篩選；所有卡片只保留公開後設資料和官方原始連結。
部分同步：ASCO Publications、SITC News Releases、SITC Annual Meeting 暫時無法使用。
當前來源：全部來源 · 主題：全部主題 · 25 條 · 每頁 10 條
AUA 2026 mPC 五大趋势：triplet 梯度、PSMA-PET、PSMAddition、survivorship、AI gap
读 50 篇 AUA 2026 advanced / metastatic 前列腺癌 abstract：triplet 强度梯度、PSMA-PET 分期重划、PSMAddition、survivorship 升格为一节，以及还没收掉的缺席。
檢視 AAI 原始來源Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis, according to a study published in Clinical Cancer Research. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源AUA 2026 — AI 和机器人都到了，但它们还没见过面
621 篇摘要，每五篇一篇。单孔领先、LLM 到场、AI 与机器人交集近乎空白。
檢視 AAI 原始來源
AACR CEO Margaret Foti, PhD, MD (hc): Thank you for an incredible AACR Annual Meeting 2026! - AACR Annual Meeting News
The AACR Annual Meeting 2026 featured a spectacular display of the progress that is being made against cancer due to your tremendous efforts. All of you—cancer researchers, clinicians, other health care profes... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Emerging Frontiers in Oncology to Support AACR and Early-Career Investigators Through Annual Oncology Summit
The American Association for Cancer Research (AACR) today thanked Emerging Frontiers in Oncology (EFO) for its support of the cancer research workforce through fundraising associated with the 8th Annual Emergi... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源AACR 2026：头颈癌迎来全新管线
358 篇 HNSCC 摘要、新治疗架构、多元生物标记、三条对抗免疫治疗耐药性的路线。
檢視 AAI 原始來源
Closing Plenary Session examined highlights from the AACR Annual Meeting 2026 - AACR Annual Meeting News
Katerina A. Politi, PhD, identified takeaways emerging from presentations in basic and translational science, including that fundamental insights into cancer biology are revealing new strategies to treat cance... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Fifth Plenary Session spotlighted new treatment modalities transforming the oncology landscape - AACR Annual Meeting News
Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a fo... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Final New Drugs on the Horizon session completed the series with the last four novel molecules - AACR Annual Meeting News
Presenters described a first-in-class inhibitor of cyclin A/B-substrate interaction, a molecular glue degrader for the treatment of acute myeloid leukemia, a novel antibody-drug conjugate, and a dual T-cell ag... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
Fourth Plenary Session explored generational trends and possible drivers of early-onset cancers - AACR Annual Meeting News
Andrew T. Chan, MD, MPH, chaired the session, which examined the rising incidence of early-onset cancers and the potential contributions of obesity, bacterial exposures, and weaning to this trend. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源